Prothena Corp. (PRTA) Announces Data from Phase 1/2 Clinical Trial of NEOD001 in AL Amyloidosis Published in Journal of Clinical Oncology
Tweet Send to a Friend
Prothena Corporation plc (NASDAQ: PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
